Masters of Longevity - The Pulse

PR Newswire18 Jun 2026
AICoreline Soft and Mint Medical Announce Partnership to Advance AI-Enabled Lung Cancer Screening (PR Newswire)

Coreline Soft and Mint Medical Announce Partnership to Advance AI-Enabled Lung Cancer Screening

How integrated AI imaging and structured reporting aim to operationalize national lung cancer screening workflows and enable scalable multi-site follow-up.

Key takeaways
  • Coreline Soft's AVIEW has been applied in over 2.5 million clinical reads worldwide.
  • Integration enables AI-detected nodules to feed Lung-RADS and VDT follow-up planning.
  • Partnership targets Germany's new LDCT screening framework and intends international scalability.
Longevity Technology18 Jun 2026
AICognition Therapeutics secures 20-year US patent for Alzheimer’s and dementia drug (Longevity Technology)

Cognition Therapeutics secures 20-year US patent for Alzheimer’s and dementia drug

Biotech IP and strategy briefing exploring how a company's recent intellectual-property development could influence its clinical and commercial planning.

Key takeaways
  • USPTO issued a Notice of Allowance for a crystalline formulation patent extending protection through 2045.
  • Company can seek a five-year patent term extension to extend protection to 2050.
  • Use this formulation in planned registrational trials for DLB psychosis.
PR Newswire18 Jun 2026
AIHuawei Expands Health and Fitness Ecosystem on HUAWEI WATCH FIT 5 Series, Deepening Commitment to Women (PR Newswire)

Huawei Expands Health and Fitness Ecosystem on HUAWEI WATCH FIT 5 Series, Deepening Commitment to Women

New wearable integrations expand women's health and fitness apps, developer tools, and subscription incentives to broaden the platform's app ecosystem reach.

Key takeaways
  • Applications are available through HUAWEI AppGallery across all models of the HUAWEI WATCH FIT 5 Series.
  • New HUAWEI WATCH FIT 5 Series buyers will receive an exclusive three-month premium subscription.
  • Founded by renowned running coach Candela Pérez.
Longevity Technology18 Jun 2026
AIAlzeCure clears key hurdle for drug targeting Alzheimer’s and depression (Longevity Technology)

AlzeCure clears key hurdle for drug targeting Alzheimer’s and depression

Read about clinical progress demonstrating safety and CNS exposure for a neurotrophic small molecule targeting dementia and mood disorders.

Key takeaways
  • ACD856 was well tolerated with no substance-related safety findings.
  • Results support Phase II studies expected in 2026 following a 2025 European Innovation Council grant.
  • Repeated higher dosing produced expected increases in blood and cerebrospinal fluid concentrations.